434 related articles for article (PubMed ID: 27558343)
1. Neutrophils in cancer.
Treffers LW; Hiemstra IH; Kuijpers TW; van den Berg TK; Matlung HL
Immunol Rev; 2016 Sep; 273(1):312-28. PubMed ID: 27558343
[TBL] [Abstract][Full Text] [Related]
2. Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization.
Groth C; Weber R; Lasser S; Özbay FG; Kurzay A; Petrova V; Altevogt P; Utikal J; Umansky V
Int J Cancer; 2021 Nov; 149(9):1628-1638. PubMed ID: 34224592
[TBL] [Abstract][Full Text] [Related]
3. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells.
Moses K; Brandau S
Semin Immunol; 2016 Apr; 28(2):187-96. PubMed ID: 27067179
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
Ostrand-Rosenberg S; Fenselau C
J Immunol; 2018 Jan; 200(2):422-431. PubMed ID: 29311384
[TBL] [Abstract][Full Text] [Related]
5. The diversity of circulating neutrophils in cancer.
Mishalian I; Granot Z; Fridlender ZG
Immunobiology; 2017 Jan; 222(1):82-88. PubMed ID: 26874580
[TBL] [Abstract][Full Text] [Related]
6. Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance.
Furumaya C; Martinez-Sanz P; Bouti P; Kuijpers TW; Matlung HL
Front Immunol; 2020; 11():2100. PubMed ID: 32983165
[TBL] [Abstract][Full Text] [Related]
7. Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells.
Zhou J; Nefedova Y; Lei A; Gabrilovich D
Semin Immunol; 2018 Feb; 35():19-28. PubMed ID: 29254756
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.
Netherby CS; Abrams SI
Cancer Immunol Immunother; 2017 Aug; 66(8):989-996. PubMed ID: 28224211
[TBL] [Abstract][Full Text] [Related]
9. MDSC; the Most Important Cell You Have Never Heard Of.
Tesi RJ
Trends Pharmacol Sci; 2019 Jan; 40(1):4-7. PubMed ID: 30527590
[TBL] [Abstract][Full Text] [Related]
10. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
Front Immunol; 2018; 9():398. PubMed ID: 29552012
[TBL] [Abstract][Full Text] [Related]
11. Plasticity of myeloid-derived suppressor cells in cancer.
Tcyganov E; Mastio J; Chen E; Gabrilovich DI
Curr Opin Immunol; 2018 Apr; 51():76-82. PubMed ID: 29547768
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.
Toor SM; Elkord E
Immunol Cell Biol; 2018 Oct; 96(9):888-897. PubMed ID: 29635843
[TBL] [Abstract][Full Text] [Related]
13. Targeting Myeloid-Derived Suppressor Cells in Cancer.
Anani W; Shurin MR
Adv Exp Med Biol; 2017; 1036():105-128. PubMed ID: 29275468
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.
Ibáñez-Vea M; Zuazo M; Gato M; Arasanz H; Fernández-Hinojal G; Escors D; Kochan G
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):113-123. PubMed ID: 29032490
[TBL] [Abstract][Full Text] [Related]
15. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.
Tuettenberg A; Steinbrink K; Schuppan D
Nanomedicine (Lond); 2016 Oct; 11(20):2735-2751. PubMed ID: 27658725
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil Heterogeneity in Cancer: From Biology to Therapies.
Lecot P; Sarabi M; Pereira Abrantes M; Mussard J; Koenderman L; Caux C; Bendriss-Vermare N; Michallet MC
Front Immunol; 2019; 10():2155. PubMed ID: 31616408
[TBL] [Abstract][Full Text] [Related]
17. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
Front Immunol; 2018; 9():2250. PubMed ID: 30349530
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells as effectors of immune suppression in cancer.
Pyzer AR; Cole L; Rosenblatt J; Avigan DE
Int J Cancer; 2016 Nov; 139(9):1915-26. PubMed ID: 27299510
[TBL] [Abstract][Full Text] [Related]
19. Targeting the myeloid microenvironment in neuroblastoma.
Stip MC; Teeuwen L; Dierselhuis MP; Leusen JHW; Krijgsman D
J Exp Clin Cancer Res; 2023 Dec; 42(1):337. PubMed ID: 38087370
[TBL] [Abstract][Full Text] [Related]
20. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities.
Lu C; Rong D; Zhang B; Zheng W; Wang X; Chen Z; Tang W
Mol Cancer; 2019 Aug; 18(1):130. PubMed ID: 31464625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
